Should I buy or sell Myomo stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MYO shares. View MYO analyst ratings or view top-rated stocks .

What is Myomo's stock price target for 2024?

2 Wall Street research analysts have issued 12 month price objectives for Myomo's shares. Their MYO share price targets range from $6.50 to $6.50. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 109.7% from the stock's current price. View analysts price targets for MYO or view top-rated stocks among Wall Street analysts .

How have MYO shares performed in 2024?

Myomo's stock was trading at $4.74 at the beginning of 2024. Since then, MYO stock has decreased by 34.6% and is now trading at $3.10. View the best growth stocks for 2024 here .

How were Myomo's earnings last quarter?

Myomo, Inc. (NYSEAMERICAN:MYO) issued its earnings results on Thursday, March, 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. The firm earned $4.76 million during the quarter, compared to analysts' expectations of $4.70 million. Myomo had a negative trailing twelve-month return on equity of 84.72% and a negative net margin of 42.34%.

What guidance has Myomo issued on next quarter's earnings?

Myomo issued an update on its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.1 million-$4.3 million, compared to the consensus revenue estimate of $4.5 million.

What other stocks do shareholders of Myomo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA) , Agile Therapeutics (AGRX) , Sarepta Therapeutics (SRPT) , Aclaris Therapeutics (ACRS) , Remark (MARK) , Synergy Pharmaceuticals (SGYP) , VBI Vaccines (VBIV) , Athersys (ATHX) and Anavex Life Sciences (AVXL) .

How do I buy shares of Myomo?

Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:MYO

Myomo (MYO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free MYO Stock Alerts

$3.19

+0.37 (+13.12%)

(As of 05:21 PM ET)

Compare

Today's Range: $2.85
▼
$3.24
50-Day Range: N/A
52-Week Range: $0.37
▼
$5.58

Volume: 323,909 shs
Average Volume: 375,767 shs
Market Capitalization: $90.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.50

Get Myomo alerts:

Myomo MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 109.7% Upside
$6.50 Price Target
Short Interest: Healthy
3.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$175,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.18) to ($0.05) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.70 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Myomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Myomo has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.26% of the float of Myomo has been sold short.
Short Interest Ratio / Days to Cover
Myomo has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Myomo has recently increased by 15.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Myomo does not currently pay a dividend.
Dividend Growth
Myomo does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MYO.

0.0

News and Social Media Coverage

Search Interest
Only 5 people have searched for MYO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Myomo to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Myomo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $175,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Myomo is held by insiders.
Percentage Held by Institutions
44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Myomo are expected to grow in the coming year, from ($0.18) to ($0.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Myomo is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Myomo is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Myomo has a P/B Ratio of 9.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Myomo Stock (NYSEAMERICAN:MYO)

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, which includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprise of 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

MYO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MYO Stock News Headlines

March 19, 2024 | insidertrades.com

Myomo, Inc. (NYSEAMERICAN:MYO) Director Purchases $175,000.00 in Stock

March 30, 2024 | investing.com

Myomo appoints Heather Getz to board of directors

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 28, 2024 | businesswire.com

Myomo Appoints Heather Getz to its Board of Directors

March 28, 2024 | businesswire.com

Myomo Appoints Heather Getz to its Board of Directors

March 18, 2024 | ca.sports.yahoo.com

Colby Covington reacts to Jorge Masvidal vs. Nate Diaz boxing match: ‘Sloppy, old f*cking dudes’

March 18, 2024 | finance.yahoo.com

Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)

March 13, 2024 | seekingalpha.com

Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 10, 2024 | seekingalpha.com

Myomo, Inc.: In Motion To Accelerating Revenue Growth

March 9, 2024 | seekingalpha.com

Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript

March 9, 2024 | markets.businessinsider.com

Myomo Inc.: Strong Growth and Regulatory Tailwinds Support Buy Rating

March 8, 2024 | finance.yahoo.com

Myomo, Inc. (AMEX:MYO) Q4 2023 Earnings Call Transcript

March 7, 2024 | investorplace.com

MYO Stock Earnings: Myomo Misses EPS, Misses Revenue for Q4 2023

March 7, 2024 | msn.com

Myomo GAAP EPS of -$0.07 misses by $0.01, revenue of $4.76M misses by $0.06M

March 7, 2024 | businesswire.com

Myomo Reports Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | msn.com

Myomo Q4 2023 Earnings Preview

March 6, 2024 | finance.yahoo.com

MYO Mar 2024 7.500 call

March 6, 2024 | benzinga.com

Myomo Earnings Preview

March 6, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Myomo's earnings

March 1, 2024 | finance.yahoo.com

CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®

February 29, 2024 | businesswire.com

Myomo to Report Fourth Quarter Financial Results on March 7, 2024

February 28, 2024 | finance.yahoo.com

Myomo, Inc. (MYO) Stock Historical Prices & Data - Yahoo Finance

January 19, 2024 | finance.yahoo.com

Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

January 17, 2024 | marketwatch.com

Myomo Stock Rises 6% After 4Q Preliminary Results

January 17, 2024 | msn.com

Myomo announces $6M registered direct offering of common stock

January 17, 2024 | finance.yahoo.com

Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

See More Headlines

Receive MYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myomo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:MYO
CUSIP: N/A
CIK: 1369290
Web: myomo.com
Phone: (617) 996-9058
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.50
High Stock Price Target: $6.50
Low Stock Price Target: $6.50
Potential Upside/Downside: +113.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,150,000.00
Net Margins: -42.34%
Pretax Margin: -41.54%
Return on Equity: -84.72%
Return on Assets: -55.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.49
Quick Ratio: 2.16

Sales & Book Value

Annual Sales: $19.24 million
Price / Sales: 4.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.34 per share
Price / Book: 8.94

Miscellaneous

Outstanding Shares: 28,490,000
Free Float: 27,575,000
Market Cap: $86.61 million
Optionable: Not Optionable
Beta: 1.52

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Paul R. Gudonis (Age 69)
Chairman, President & CEO
Comp: $358.79k
Mr. David A. Henry (Age 63)
Chief Financial Officer
Comp: $273.1k
Dr. Harry Kovelman M.D. (Age 65)
Chief Medical Officer
Comp: $277.58k
Colin Anderson
Global Director of Operations
Mr. Joseph Chicoskie
Director of Marketing
Ms. Galina Shtivelman
Senior Director of Human Resources
Mr. Micah J. Mitchell (Age 48)
Chief Commercial Officer
Comp: $317.39k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MYO Stock Analysis - Frequently Asked Questions

Should I buy or sell Myomo stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MYO shares.
View MYO analyst ratings or view top-rated stocks.
What is Myomo's stock price target for 2024?: 2 Wall Street research analysts have issued 12 month price objectives for Myomo's shares. Their MYO share price targets range from $6.50 to $6.50. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 109.7% from the stock's current price.
View analysts price targets for MYO or view top-rated stocks among Wall Street analysts.
How have MYO shares performed in 2024?: Myomo's stock was trading at $4.74 at the beginning of 2024. Since then, MYO stock has decreased by 34.6% and is now trading at $3.10.
View the best growth stocks for 2024 here.
How were Myomo's earnings last quarter?: Myomo, Inc. (NYSEAMERICAN:MYO) issued its earnings results on Thursday, March, 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. The firm earned $4.76 million during the quarter, compared to analysts' expectations of $4.70 million. Myomo had a negative trailing twelve-month return on equity of 84.72% and a negative net margin of 42.34%.

What guidance has Myomo issued on next quarter's earnings?: Myomo issued an update on its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.1 million-$4.3 million, compared to the consensus revenue estimate of $4.5 million.
What other stocks do shareholders of Myomo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Synergy Pharmaceuticals (SGYP), VBI Vaccines (VBIV), Athersys (ATHX) and Anavex Life Sciences (AVXL).
How do I buy shares of Myomo?: Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:MYO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial